The National Health Service (NHS) in England has officially begun offering a subcutaneous injection for cancer immunotherapy. This breakthrough reduces the drug administration time for patients from several hours to approximately one minute.
A shift from intravenous infusion to subcutaneous injection Previously, patients treated with pembrolizumab (brand name Keytruda) underwent intravenous infusions lasting one to two hours. With the new technique:
-
Administration time: The injection process takes only one to two minutes.
-
Medical efficiency: It cuts hospital stay time by 90%, allowing the NHS to accommodate more patients and alleviate resource strain.
-
Scope of application: Approximately 14,000 patients annually in the UK, including those with lung, breast, cervical, and head and neck cancers, are expected to transition to this convenient method.
Mechanism and scientific significance The therapy is based on research that garnered the 2018 Nobel Prize in Medicine.
-
How it works: The drug disables the “invisibility cloak” used by cancer cells to evade the immune system, enabling the body’s natural defenses to identify and destroy tumors.
-
Development: This is the third immunotherapy drug the NHS has converted to an injectable format. Keytruda stands as one of the most commercially successful pharmaceuticals in history, with cumulative sales estimated at $180 billion.
Impact on patients and the healthcare system Beyond optimizing hospital resources, this method offers significant emotional value to patients. Reducing grueling wait times allows patients more time for their personal lives and families. Economically, while specific agreement details remain confidential, the NHS confirmed that the cost for the injectable version is nearly equivalent to the intravenous one, ensuring healthcare budget sustainability.